Form 4: Lipella Pharmaceuticals Director Kaufman Increases Stake with $7,590 Stock Purchase

Director Jonathan H. Kaufman of Lipella Pharmaceuticals Inc. (LIPO) purchased 10,000 shares of common stock at an average price of $0.759 on May 14, 2024, increasing his total holdings.

Summary

• On May 14, 2024, Jonathan H. Kaufman, a director, 10% owner, and officer (President, CEO, Secretary, Treasurer, and Chairman of the Board) of Lipella Pharmaceuticals Inc., purchased 10,000 shares of the company's common stock.
• The shares were acquired through open market purchases at a weighted average price of $0.759 per share, for a total transaction value of $7,590.
• The purchases were made in multiple transactions with prices ranging from $0.7552 to $0.76 per share.
• Following the reported transaction, Kaufman directly owns 898,849 shares of Lipella Pharmaceuticals Inc. common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment. It's a routine disclosure of an insider purchase. While insider buying can be seen as a positive signal, it's not overwhelmingly bullish.

Positives

• The director's purchase of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider buying is often monitored by investors as it can provide insights into management's view of the company's prospects. However, it's just one data point and should be considered alongside other factors.

Stakeholder Impact

• The stock purchase could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Lipella Pharmaceuticals, insider trading, stock purchase, Jonathan Kaufman, LIPO, Form 4, beneficial ownership